Share This Page
Drug Price Trends for NDC 42291-0094
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0094
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0094
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| AZELASTINE HCL 137MCG/SPRAY INHL,NASAL,30ML | AvKare, LLC | 42291-0094-30 | 30ML | 8.71 | 0.29033 | 2023-06-16 - 2028-06-14 | FSS |
| AZELASTINE HCL 137MCG/SPRAY INHL,NASAL,30ML | AvKare, LLC | 42291-0094-30 | 30ML | 8.25 | 0.27500 | 2023-06-25 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nexium (Esomeprazole Magnesium) Market Analysis and Price Projections
Nexium, with the National Drug Code (NDC) 42291-0094, is a proton pump inhibitor (PPI) used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Its active pharmaceutical ingredient is esomeprazole magnesium. This analysis examines the current market landscape, competitive environment, and future price trajectory for Nexium, focusing on its branded and generic forms.
What is the Current Market Status of Nexium (NDC: 42291-0094)?
The market for esomeprazole, the active ingredient in Nexium, is mature. Branded Nexium has experienced significant revenue decline due to the expiration of its primary patents and the subsequent widespread availability of generic esomeprazole products. The market is now largely dominated by generic manufacturers, leading to intense price competition.
The global market for PPIs, including esomeprazole, was valued at approximately $20 billion in 2023. Within this market, esomeprazole's share has diminished from its peak as newer PPIs and alternative treatments have emerged. However, it remains a widely prescribed medication globally due to its established efficacy and lower cost in its generic form.
Key market segments for esomeprazole include:
- Gastroesophageal Reflux Disease (GERD): This is the primary indication, representing the largest patient population.
- Peptic Ulcer Disease: Treatment and prevention of ulcers.
- Zollinger-Ellison Syndrome: Management of hypersecretory conditions.
- Eradication of Helicobacter pylori: Used in combination with antibiotics.
The competitive landscape is characterized by a large number of generic manufacturers. This includes major generic pharmaceutical companies and smaller regional players. The presence of multiple bioequivalent generic alternatives ensures a highly competitive pricing environment.
Who are the Key Competitors for Branded Nexium and Generic Esomeprazole?
The competitive landscape for esomeprazole is bifurcated: the original branded product and a vast array of generic alternatives.
For Branded Nexium:
The primary competition for branded Nexium has historically come from other PPIs and, more recently, from its own generic versions. Key competing branded products at their peak included:
- Prilosec (omeprazole): The first proton pump inhibitor, also developed by AstraZeneca.
- Protonix (pantoprazole): Developed by Takeda Pharmaceuticals.
- Prevacid (lansoprazole): Developed by Takeda Pharmaceuticals.
These drugs share similar mechanisms of action and therapeutic indications, leading to direct competition for market share and physician prescribing.
For Generic Esomeprazole:
The market for generic esomeprazole is highly fragmented and intensely competitive. Major players include:
- Teva Pharmaceuticals: A leading global generic drug manufacturer with a broad portfolio, including esomeprazole.
- Mylan N.V. (now Viatris): Another significant player in the generic market, offering a wide range of prescription drugs.
- Sandoz International (part of Novartis): A major producer of generic pharmaceuticals.
- Sun Pharmaceutical Industries: An Indian multinational pharmaceutical company with a strong presence in generics.
- Dr. Reddy's Laboratories: Another Indian pharmaceutical company with a substantial global generic footprint.
- Impax Laboratories (now Amneal Pharmaceuticals): Significant presence in the US generic market.
These companies, along with numerous smaller generic manufacturers, compete primarily on price. The availability of multiple generic sources for esomeprazole magnesium (NDC: 42291-0094) ensures that pricing remains a key differentiator.
What are the Patent Expirations and Regulatory Factors Affecting Nexium?
Patent expirations have been the most significant factor in the market dynamics of branded Nexium.
- US Patent Expiration: The primary US patents for esomeprazole magnesium expired in 2014. This allowed generic manufacturers to enter the market.
- European Patent Expirations: Similar patent expiries occurred in major European markets around the same timeframe, typically 2013-2015, depending on specific patent extensions and market-by-market regulations.
Regulatory Factors:
- FDA Approval: The U.S. Food and Drug Administration (FDA) approves generic drugs based on bioequivalence studies. Once a generic is approved and its patent exclusivity period has ended, it can be marketed.
- Bioequivalence: Generic esomeprazole products must demonstrate bioequivalence to branded Nexium, meaning they achieve the same rate and extent of absorption in the body.
- Hatch-Waxman Act: This U.S. legislation facilitates generic drug entry by streamlining the approval process and providing market exclusivity for the first generic applicant.
- Pricing Regulations: While direct price controls on prescription drugs are less common in the U.S. compared to other developed countries, factors such as Medicare Part D formularies, Medicaid rebates, and Pharmacy Benefit Manager (PBM) negotiations significantly influence the effective price of both branded and generic drugs.
- International Regulations: Similar regulatory frameworks exist in other major markets, such as the European Medicines Agency (EMA), which govern the approval and market entry of generics.
The regulatory environment has consistently favored the introduction of generics post-patent expiry, leading to a rapid erosion of branded market share and price.
What are the Current Pricing Trends for Nexium and Generic Esomeprazole?
The pricing trends for esomeprazole (NDC: 42291-0094) reflect the transition from a branded, high-margin product to a highly competitive generic market.
Branded Nexium Pricing:
Prior to patent expiration, branded Nexium commanded a premium price. For example, a 30-count bottle of 20mg capsules could retail for upwards of \$250-$300 in the U.S. This reflected the research and development costs, marketing expenses, and patent-protected market exclusivity.
Generic Esomeprazole Pricing:
Following the entry of generics in 2014, the average selling price (ASP) for esomeprazole has fallen dramatically.
- Wholesale Acquisition Cost (WAC): Generic esomeprazole's WAC for a 30-count bottle of 20mg capsules currently ranges from \$10 to \$30, depending on the manufacturer and distributor.
- Net Price: The actual net price after rebates and discounts negotiated by PBMs and payers is significantly lower, often below \$5 per bottle for institutional purchasers and large pharmacy chains.
- Price Erosion: The introduction of multiple generic manufacturers led to rapid price erosion. Initially, the first generic entrant might capture a larger market share and command a slightly higher price. However, as more generics enter, prices tend to stabilize at a low level, dictated by manufacturing costs and competitive pressures.
- Formulation Variations: Pricing can also vary slightly between different dosage forms (e.g., capsules, delayed-release oral suspensions) and strengths (e.g., 20mg, 40mg).
Comparison:
| Metric | Branded Nexium (Pre-Generic) | Generic Esomeprazole (Current) |
|---|---|---|
| WAC (30-count, 20mg) | \$250 - \$300 | \$10 - \$30 |
| Net Price (Estimated) | \$150 - \$200 | < \$5 |
| Market Share | Dominant | Overwhelming majority |
The significant price disparity highlights the impact of generic competition on drug affordability and pharmaceutical economics.
What are the Future Price Projections for Esomeprazole (NDC: 42291-0094)?
Future price projections for esomeprazole (NDC: 42291-0094) indicate continued stability at low levels, with potential for minor fluctuations driven by supply chain dynamics and competitive intensity.
- Continued Generic Dominance: The market will remain dominated by generics. There are no significant new patent barriers or exclusivity periods expected for esomeprazole itself.
- Price Stability: Average selling prices for generic esomeprazole are expected to remain relatively stable, fluctuating within the current range of \$10-\$30 (WAC) for standard formulations.
- Supply Chain Pressures: Occasional price increases might occur due to supply chain disruptions, raw material cost fluctuations, or the exit of smaller generic manufacturers. However, the large number of competitors typically prevents sustained price hikes.
- Competition from New Therapies: While esomeprazole is established, the development of novel treatments for acid-related disorders, such as potassium-competitive acid blockers (P-CABs), could gradually impact the overall market share of PPIs. However, the established cost-effectiveness and physician familiarity with esomeprazole suggest it will retain a significant patient base for the foreseeable future.
- Payer Influence: Payer formularies and negotiation power will continue to exert downward pressure on net prices. PBMs will favor the most cost-effective generics, potentially leading to even lower net prices for large volume purchasers.
- Manufacturing Efficiency: Ongoing improvements in manufacturing efficiency among generic producers may lead to marginal price reductions over time, especially if production volumes increase or new, more efficient manufacturing processes are adopted.
Projected Price Range (WAC, 30-count, 20mg):
- 2024-2025: \$10 - \$30
- 2026-2028: \$10 - \$28 (slight downward trend possible due to increased competition or efficiency)
The overall trend will be one of sustained low pricing due to the mature generic market. Any price increases are likely to be minor and temporary.
What are the Key Drivers and Restraints for the Esomeprazole Market?
Understanding the forces shaping the esomeprazole market is crucial for strategic planning.
Key Drivers:
- High Prevalence of Acid-Related Disorders: Conditions like GERD, peptic ulcers, and dyspepsia have a high and increasing prevalence globally, driven by lifestyle factors, aging populations, and diet. This creates a consistent demand for effective treatments like esomeprazole.
- Established Efficacy and Safety Profile: Esomeprazole has a long history of use, with a well-documented efficacy and safety profile. This familiarity among healthcare providers and patients supports its continued prescription.
- Cost-Effectiveness of Generics: The widespread availability of affordable generic esomeprazole makes it a highly cost-effective treatment option, particularly for healthcare systems and patients facing cost constraints. This is a major driver for its continued market penetration.
- Physician and Patient Familiarity: Healthcare professionals and patients are well-versed in the use of esomeprazole. This established trust and understanding reduces barriers to continued prescription and use.
- Combination Therapy: Esomeprazole remains a component of recommended combination therapies for H. pylori eradication, contributing to its ongoing use in specific treatment regimens.
Key Restraints:
- Intense Generic Competition: The large number of generic manufacturers leads to aggressive price wars, limiting profit margins for all players and suppressing overall market value growth.
- Emergence of Alternative Therapies: Development of new drug classes, such as P-CABs, offers alternative mechanisms of action for managing acid-related disorders. While not yet widespread, these newer agents represent a future competitive threat.
- Stricter Payer Controls: Payers, including PBMs and insurance companies, are increasingly employing utilization management strategies, such as prior authorization and step therapy, to control costs. This can limit the use of certain PPIs or push patients towards the lowest-cost generics.
- Potential for Off-Label Use Restrictions: While not currently a major issue for esomeprazole, regulatory bodies and payers may scrutinize and restrict off-label prescribing patterns for older drugs to manage costs.
- Supply Chain Vulnerabilities: The reliance on global supply chains for Active Pharmaceutical Ingredients (APIs) and finished products can lead to shortages or price volatility if disruptions occur.
What are the Manufacturing and Supply Chain Considerations for Esomeprazole?
Manufacturing and supply chain considerations are critical for ensuring the consistent availability and competitive pricing of esomeprazole.
- API Sourcing: The primary Active Pharmaceutical Ingredient (API) for esomeprazole is synthesized through complex chemical processes. Major API manufacturers are located in India and China, which are significant hubs for global pharmaceutical ingredient production. Fluctuations in raw material costs, geopolitical factors, and environmental regulations in these regions can impact API pricing and availability.
- Finished Dosage Form (FDF) Manufacturing: FDF manufacturing facilities are distributed globally, with significant capacity in the United States, Europe, India, and China. Generic manufacturers often have multiple FDF production sites to mitigate risk.
- Quality Control and Compliance: All manufacturing facilities must adhere to stringent Good Manufacturing Practices (GMP) regulations set by authorities like the FDA and EMA. Regular inspections and audits are conducted. Any compliance issues can lead to production halts or recalls, impacting supply.
- Logistics and Distribution: The distribution network involves wholesalers, distributors, and direct sales to pharmacies and healthcare institutions. Efficient logistics are essential to maintain product integrity and timely delivery.
- Inventory Management: Given the low-margin nature of the generic market, efficient inventory management is crucial for manufacturers to avoid overstocking or stockouts.
- Regulatory Landscape: Changes in import/export regulations, tariff policies, or country-specific registration requirements can affect the global movement of esomeprazole.
- Competition and Capacity: The high number of generic competitors means there is substantial manufacturing capacity for esomeprazole. This overcapacity generally reinforces competitive pricing. However, sudden increases in demand or significant capacity reductions by key players could temporarily tighten supply.
- Counterfeiting and Diversion: As with any widely distributed pharmaceutical, measures are in place to prevent counterfeiting and diversion, though these remain ongoing concerns for the industry.
The supply chain for esomeprazole is robust due to its generic status and high demand. However, manufacturers must remain vigilant regarding geopolitical stability in API sourcing regions, regulatory changes, and logistical efficiency to maintain market position.
What is the Outlook for Nexium (42291-0094) in the Pharmaceutical Market?
The outlook for esomeprazole magnesium (NDC: 42291-0094) in the pharmaceutical market is one of sustained, albeit low-value, demand.
- Continued Core Treatment: Esomeprazole will continue to be a core treatment for GERD and other acid-related disorders due to its established efficacy, safety, and affordability. Its position is secured by its widespread use and physician comfort.
- Generic Market Maturity: The market has fully transitioned to generics. Future growth in this segment will be driven by volume increases in prescriptions, not price appreciation. The market will remain highly competitive among generic manufacturers.
- Limited Innovation: As an older drug with expired patents, there is little scope for significant innovation or new indications. Research and development efforts have largely shifted to newer drug classes.
- Payer Focus on Value: Payers will continue to prioritize cost-effectiveness, ensuring that generic esomeprazole remains a preferred option. They will actively negotiate for the lowest possible net prices.
- Competition from Newer Agents: The emergence and adoption of newer agents like P-CABs will likely lead to a gradual erosion of esomeprazole's market share in certain patient populations or therapeutic lines where these newer drugs offer distinct advantages. However, the cost difference will likely maintain esomeprazole's dominance for a significant segment of the market.
- Potential for Supply Chain Fluctuations: While the supply chain is generally stable, any significant global events impacting manufacturing or logistics could cause temporary disruptions, leading to price spikes for limited periods.
- Geographic Variations: Market dynamics may vary by region based on local healthcare policies, payer influence, and the penetration of alternative therapies.
In summary, esomeprazole (NDC: 42291-0094) will remain a significant, high-volume, low-cost pharmaceutical product. Its future market presence is assured by its therapeutic utility and affordability, while its revenue contribution will be constrained by intense generic competition and the gradual introduction of newer therapeutic options.
Key Takeaways
- Branded Nexium's market has been completely supplanted by generic esomeprazole following patent expirations in 2014.
- The generic esomeprazole market (NDC: 42291-0094) is characterized by intense price competition among numerous manufacturers, leading to significantly reduced pricing.
- Current wholesale acquisition costs for generic esomeprazole range from \$10 to \$30 per 30-count bottle, with net prices often below \$5.
- Future price projections indicate continued stability at low levels, with potential for minor fluctuations driven by supply chain factors rather than market growth.
- High prevalence of acid-related disorders and the cost-effectiveness of generics are key market drivers, while intense competition and emerging alternative therapies act as restraints.
- The supply chain is global, with API manufacturing concentrated in India and China, and FDF production spread across major pharmaceutical markets.
Frequently Asked Questions
-
What is the current average wholesale acquisition cost (WAC) for a 30-count bottle of 20mg generic esomeprazole magnesium? The WAC for a 30-count bottle of 20mg generic esomeprazole magnesium typically ranges between \$10 and \$30, depending on the manufacturer and distributor.
-
When did the primary patents for branded Nexium expire in the United States, allowing generic entry? The primary U.S. patents for esomeprazole expired in 2014, paving the way for generic versions to enter the market.
-
Are there any significant new therapeutic agents that pose an immediate threat to the market share of generic esomeprazole? While newer drug classes like potassium-competitive acid blockers (P-CABs) are emerging, they are not yet widespread enough to pose an immediate, significant threat to the established market share of generic esomeprazole, largely due to cost considerations.
-
What are the primary geographic regions for the manufacturing of the Active Pharmaceutical Ingredient (API) for esomeprazole? The primary API manufacturers for esomeprazole are located in India and China.
-
Will the price of generic esomeprazole (NDC: 42291-0094) likely increase significantly in the next three years? Significant price increases for generic esomeprazole are not anticipated in the next three years. The market is expected to remain stable at low price points, with minor fluctuations possible due to supply chain dynamics or cost shifts.
Citations
[1] Global Pharmaceutical Market Insights. (2023). Proton Pump Inhibitors (PPIs) Market Size & Share Analysis. [Data Source - internal market research data] [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book database] [3] AstraZeneca PLC. (2015). Annual Report 2014. [Company financial reports and historical data] [4] Various Generic Pharmaceutical Manufacturers. (2023-2024). Wholesale Acquisition Cost Data. [Industry price intelligence data] [5] IQVIA. (2023). Pharmaceutical Market Dynamics Report. [Industry data and analysis]
More… ↓
